RU2633236C2 - Способы и композиции для лечения болезни рейно - Google Patents

Способы и композиции для лечения болезни рейно Download PDF

Info

Publication number
RU2633236C2
RU2633236C2 RU2013141836A RU2013141836A RU2633236C2 RU 2633236 C2 RU2633236 C2 RU 2633236C2 RU 2013141836 A RU2013141836 A RU 2013141836A RU 2013141836 A RU2013141836 A RU 2013141836A RU 2633236 C2 RU2633236 C2 RU 2633236C2
Authority
RU
Russia
Prior art keywords
composition
prostaglandin
dimethylamino
semi
affected part
Prior art date
Application number
RU2013141836A
Other languages
English (en)
Russian (ru)
Other versions
RU2013141836A (ru
Inventor
Дэниел В. ФРЭНК
Ричард Мартин
Бассам Б. ДАМАЖ
Original Assignee
Нексмед Холдингс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нексмед Холдингс, Инк. filed Critical Нексмед Холдингс, Инк.
Publication of RU2013141836A publication Critical patent/RU2013141836A/ru
Application granted granted Critical
Publication of RU2633236C2 publication Critical patent/RU2633236C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2013141836A 2011-04-07 2012-04-06 Способы и композиции для лечения болезни рейно RU2633236C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472988P 2011-04-07 2011-04-07
US61/472,988 2011-04-07
PCT/US2012/032577 WO2012139033A1 (en) 2011-04-07 2012-04-06 Methods and compositions for treating raynaud's disease

Publications (2)

Publication Number Publication Date
RU2013141836A RU2013141836A (ru) 2015-05-20
RU2633236C2 true RU2633236C2 (ru) 2017-10-11

Family

ID=46969575

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013141836A RU2633236C2 (ru) 2011-04-07 2012-04-06 Способы и композиции для лечения болезни рейно

Country Status (8)

Country Link
US (4) US8940794B2 (OSRAM)
EP (1) EP2693877A4 (OSRAM)
JP (1) JP2014510156A (OSRAM)
BR (1) BR112013025744A2 (OSRAM)
CA (1) CA2838109C (OSRAM)
MX (1) MX342511B (OSRAM)
RU (1) RU2633236C2 (OSRAM)
WO (1) WO2012139033A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009918A1 (en) 2003-04-02 2005-01-13 Nexmed (Holdings) Inc. Prostaglandin compositions and methods for the treatment of vasospasm
EP2693877A4 (en) 2011-04-07 2014-11-19 Nexmed Holdings Inc METHOD AND COMPOSITION FOR TREATING RAYNAUD SYNDROME
PE20151301A1 (es) 2013-02-05 2015-09-16 Purdue Pharma Lp Formulaciones farmaceuticas resistentes a la manipulacion indebida
CN109288848A (zh) * 2018-11-27 2019-02-01 西安力邦肇新生物科技有限公司 前列腺素e1甲酯在制备扩张血管药物中的应用
WO2022032141A1 (en) * 2020-08-07 2022-02-10 Eicos Sciences, Inc. Method of treating systemic sclerosis with symptomatic raynaud's phenomenon by intravenous or subcutaneous iloprost administration
WO2025019625A1 (en) 2023-07-18 2025-01-23 Btg International Inc. Method of using iloprost for treating frostbite

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
US20080069883A1 (en) * 2003-04-02 2008-03-20 Nexmed Holdings, Inc. Prostaglandin compositions and methods for the treatment of vasospasm
RU2342386C2 (ru) * 2002-10-30 2008-12-27 Мерк Фросст Кэнада Лтд Производные пиридопирролизина и пиридоиндолизина

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029814A (en) 1975-12-29 1977-06-14 The Upjohn Company Phenyl-substituted prostaglandin-e type analogs
US4212987A (en) 1976-09-17 1980-07-15 The Upjohn Company 2,2-Difluoro-PGE1 analogs
US4311707A (en) 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4820732A (en) 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
US4955878A (en) 1986-04-04 1990-09-11 Biotechnology, Inc. Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures
DE3704825A1 (de) 1987-02-16 1988-08-25 Froelich Juergen Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung
US5219885A (en) 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
ES2093774T3 (es) 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
EP0583482B1 (en) 1992-02-07 1999-12-29 Kaken Pharmaceutical Co., Ltd. Remedy for wound or hemorrhoid
PT746294E (pt) 1993-10-07 2005-03-31 Odontex Inc Promotores de absorcao para formulacoes farmaceuticas topicas
US5380760A (en) 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
US20020165122A1 (en) 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US5952006A (en) 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
US6414028B1 (en) 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US6046244A (en) 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
TW473834B (en) 1998-05-01 2002-01-21 Ibm Method of doping a gate and creating a very shallow source/drain extension and resulting semiconductor
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US7087240B1 (en) 1998-06-25 2006-08-08 Lavipharm Laboratories Inc. Device and method for the treatment of erectile dysfunction
US6007824A (en) 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
CA2442479C (en) 1999-05-13 2005-12-13 Nexmed Holdings, Inc. Topical compositions for prostaglandin e1 delivery
US6118020A (en) 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7105571B2 (en) 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
DE60124504T2 (de) 2000-02-04 2007-09-20 Takeda Pharmaceutical Co. Ltd. Stabile emulsionszubereitungen
AU2002317041A1 (en) 2002-07-24 2004-02-09 Snp Natural Products Pty Ltd TOPICAL ANTIINFLAMMATORY PREPARATIONS OF Gamma-TERPINENE
US6841574B2 (en) 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
ES2466346T3 (es) * 2006-10-02 2014-06-10 Techfields Biochem Co. Ltd Profármacos de prostaglandinas solubles en agua con carga positiva y compuestos relacionados con índices de penetración en la piel muy altos
EP2011496A1 (en) 2007-07-03 2009-01-07 Indena S.P.A. Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions
AR068409A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
EP2693877A4 (en) * 2011-04-07 2014-11-19 Nexmed Holdings Inc METHOD AND COMPOSITION FOR TREATING RAYNAUD SYNDROME

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2342386C2 (ru) * 2002-10-30 2008-12-27 Мерк Фросст Кэнада Лтд Производные пиридопирролизина и пиридоиндолизина
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
US20080069883A1 (en) * 2003-04-02 2008-03-20 Nexmed Holdings, Inc. Prostaglandin compositions and methods for the treatment of vasospasm

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHLEZ A. et al. Systemic scleroderma patients have improved skin perfusion after the transdermal application of PGE1 ethyl ester// Vasa. 2003 May; 32(2): 83-6, реф. Ambrosioni E. et al. The pharmacology and clinical aspects of the prostanoids// Ann Ital Med Int. 1993 Oct;8 Suppl:59S-65S, реф. Yokota S. et al. Thermographic assessment of Raynaud's phenomenon in childhood mixed connective tissue disease// Ryumachi. 1994 Dec;34(6):955-60, реф. *
АЛЕКСЕЕВА Е.И. и др. Опыт применения алпростадила при синдроме Рейно у детей// Вопросы современной педиатрии, 2007, т.6, 5, с.128-131. *

Also Published As

Publication number Publication date
US10632086B2 (en) 2020-04-28
MX342511B (es) 2016-10-03
US9855231B2 (en) 2018-01-02
WO2012139033A1 (en) 2012-10-11
BR112013025744A2 (pt) 2016-08-16
US20160331761A1 (en) 2016-11-17
EP2693877A4 (en) 2014-11-19
EP2693877A1 (en) 2014-02-12
US8940794B2 (en) 2015-01-27
MX2013011662A (es) 2013-12-12
JP2014510156A (ja) 2014-04-24
CA2838109A1 (en) 2012-10-11
US9517218B2 (en) 2016-12-13
US20160081954A1 (en) 2016-03-24
RU2013141836A (ru) 2015-05-20
CA2838109C (en) 2020-06-09
US20180333377A1 (en) 2018-11-22
US20140200274A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
US10632086B2 (en) Methods and compositions for treating Raynaud's disease
AU2003220786B2 (en) Orodispersible pharmaceutical composition comprising agomelatine
Koland et al. Mucoadhesive films of losartan potassium for buccal delivery: Design and characterization
KR102802121B1 (ko) 아세나핀을 함유하는 경피 치료 시스템
HU229083B1 (en) Compositions and methods for amelioration of human female sexual dysfunction
HUE027395T2 (hu) Eszközök nyálkahártyán keresztül történõ bejuttatására, javított felszívódással
Arndts et al. Pharmacokinetics and pharmacodynamics of transdermally administered clonidine
CA2678500A1 (en) Compositions and methods for enhancing transmucosal delivery
WO2019243432A1 (en) Transdermal therapeutic system containing asenapine
Parati et al. Difference between office and ambulatory blood pressure and response to antihypertensive treatment
US20090062382A1 (en) External preparation for improving coital function
Kaleli et al. Symptomatic treatment of premenstrual mastalgia in premenopausal women with lisuride maleate: a double-blind placebo-controlled randomized study
US4842854A (en) Antianginal plate for treating ischemic heart disease
US4921695A (en) Antianginal plate for treating ischemic heart disease
WO2021056109A1 (en) Gel base composition for compounding into a mucoadhesive delivery system
EP3870176B1 (en) Use of ambrisentan for the treatment of portal hypertension
US20150320764A1 (en) Treating female sexual arousal disorder and related symptoms
JP7204477B2 (ja) 遅発相アレルギー反応抑制剤
KR102488424B1 (ko) 질내 삽입형 에스트라다이올 약제학적 조성물 및 방법
Karthik et al. FORMULATION AND EVALUTION OF TERBUTALINE SULPHATE BUCCAL PATCHES BY USING HPMC K4M, HPMC E15 POLYMERS
JPH10139687A (ja) 皮膚外用液剤
WO2014125052A1 (en) Pharmaceutical composition for oral administration comprising fexofenadine and process for preparing thereof
Mantelle et al. Oral Transmucosal Systems
JP2020172475A (ja) メロキシカム又はその薬学的に許容される塩を含有する内服治療剤
BR112019010466B1 (pt) Sistemas terapêuticos transdérmicos contendo asenapina, seus usos e processos para fabricação de uma camada matriz para uso nos ditos sistemas